Acute Lymphoid Leukemia

About
Mappings

OncoTree: Acute Lymphoid Leukemia (oncotree:ALL)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this cancer type.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
FDA (2) HC (1) CD19 + Acute Lymphoid Leukemia Blinatumomab
FDA (1) BCR::ABL1, CD19 + Acute Lymphoid Leukemia Blinatumomab
FDA (2) BCR::ABL1 Acute Lymphoid Leukemia Dasatinib
FDA (2) CD33 + Acute Lymphoid Leukemia Gemtuzumab ozogamicin
FDA (1) FLT3-ITD Acute Lymphoid Leukemia Gilteritinib
FDA (1) FLT3 p.D835Y Acute Lymphoid Leukemia Gilteritinib
FDA (1) HC (1) FLT3 p.D835A Acute Lymphoid Leukemia Gilteritinib
FDA (1) HC (1) FLT3 p.D835E Acute Lymphoid Leukemia Gilteritinib
FDA (1) HC (1) FLT3 p.D835H Acute Lymphoid Leukemia Gilteritinib
FDA (1) HC (1) FLT3 p.D835N Acute Lymphoid Leukemia Gilteritinib
FDA (1) HC (1) FLT3 p.D835S Acute Lymphoid Leukemia Gilteritinib
FDA (1) HC (1) FLT3 p.D835V Acute Lymphoid Leukemia Gilteritinib
FDA (2) HC (2) BCR::ABL1 Acute Lymphoid Leukemia Imatinib
FDA (1) HC (1) CD22 + Acute Lymphoid Leukemia Inotuzumab ozogamicin
FDA (1) BCR::ABL1 Acute Lymphoid Leukemia Cytarabine, Methotrexate, Ponatinib, Prednisone, Vincristine
FDA (1) HC (1) ABL1 p.T315I, BCR::ABL1 Acute Lymphoid Leukemia Ponatinib
FDA (1) t(KMT2A;v) Acute Lymphoid Leukemia Revumenib
FDA (1) NPM1 p.W288Cfs*12 Acute Lymphoid Leukemia Revumenib